Breachway Investments LLC Makes New $652,000 Investment in Eli Lilly and Company $LLY

Breachway Investments LLC bought a new position in shares of Eli Lilly and Company (NYSE:LLY) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 607 shares of the company’s stock, valued at approximately $652,000.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. SageGuard Financial Group LLC bought a new position in shares of Eli Lilly and Company in the 4th quarter valued at $1,352,000. RTD Financial Advisors Inc. bought a new position in Eli Lilly and Company during the 4th quarter worth $523,000. Evergreen Capital Management LLC raised its position in Eli Lilly and Company by 4.7% during the 4th quarter. Evergreen Capital Management LLC now owns 12,210 shares of the company’s stock worth $13,121,000 after purchasing an additional 543 shares during the last quarter. Private Wealth Partners LLC raised its position in Eli Lilly and Company by 12.8% during the 4th quarter. Private Wealth Partners LLC now owns 5,399 shares of the company’s stock worth $5,802,000 after purchasing an additional 612 shares during the last quarter. Finally, Legacy Advisors LLC raised its position in Eli Lilly and Company by 20.7% during the 4th quarter. Legacy Advisors LLC now owns 2,168 shares of the company’s stock worth $2,330,000 after purchasing an additional 372 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors.

Key Stories Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Analyst upgrades and higher targets provide support for the shares — firms have recently raised price targets and reiterated bullish views, which underpins medium‑term confidence in execution. Price Target Raised to $1,183.00
• Positive Sentiment: Expanded distribution partnerships broaden commercial reach: Lilly expanded its tie‑up with Hims & Hers to allow prescriptions filled via LillyDirect, increasing patient access to GLP‑1s and Zepbound. This helps commercialization and channel diversification. Eli Lilly (LLY) Expands Partnership with Hims & Hers
• Positive Sentiment: M&A and pipeline progress: recent reports list Lilly acquiring Kelonia (~$7B) and completing a Phase 1 renal study (LY3537982), which reduce early‑stage risk and add potential growth assets. These are constructive for long‑term revenue diversity. Deal Dispatch (mentions Lilly/Kelonia) LY3537982 Renal Study Reaches Completion
• Neutral Sentiment: Upcoming earnings (Q1 report due April 30) is a near‑term catalyst that can amplify moves in either direction — investors are sensitive to any GLP‑1 demand readouts ahead of that release. Weekly GLP-1 prescription data analysis
• Negative Sentiment: Foundayo rollout is tracking below expectations — second‑week U.S. prescriptions were ~3,707, a much smaller early ramp than Novo Nordisk’s oral Wegovy benchmark, raising investor concerns about near‑term obesity market share and pricing/mix. That weaker early uptake is the primary reason shares are under pressure today. Lilly’s obesity pill hits nearly 4000 prescriptions
• Negative Sentiment: Weekly GLP‑1 prescription trackers show mixed demand signals (diabetes scripts steady but obesity scripts softer), and heavy insider selling / shifting institutional flows noted in some data sources add to short‑term sentiment risk. Prescription data and insider activity

Analyst Ratings Changes

LLY has been the subject of a number of recent analyst reports. Jefferies Financial Group set a $1,300.00 price target on Eli Lilly and Company and gave the stock a “buy” rating in a report on Friday, March 13th. Daiwa Securities Group lifted their price target on Eli Lilly and Company from $1,230.00 to $1,250.00 and gave the company a “buy” rating in a research note on Wednesday, February 18th. Royal Bank Of Canada initiated coverage on Eli Lilly and Company in a research note on Tuesday, February 24th. They set an “outperform” rating and a $1,250.00 price target for the company. Bank of America lifted their price target on Eli Lilly and Company from $1,293.00 to $1,294.00 and gave the company a “buy” rating in a research note on Thursday, April 2nd. Finally, HSBC downgraded Eli Lilly and Company from a “hold” rating to a “reduce” rating and cut their price target for the company from $1,070.00 to $850.00 in a research note on Tuesday, March 17th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Eli Lilly and Company currently has an average rating of “Moderate Buy” and an average price target of $1,225.33.

Eli Lilly and Company Stock Down 3.6%

Eli Lilly and Company stock opened at $884.88 on Friday. Eli Lilly and Company has a 1-year low of $623.78 and a 1-year high of $1,133.95. The firm has a market capitalization of $836.05 billion, a price-to-earnings ratio of 38.56, a P/E/G ratio of 1.09 and a beta of 0.51. The company has a current ratio of 1.58, a quick ratio of 1.19 and a debt-to-equity ratio of 1.54. The firm has a 50 day simple moving average of $958.83 and a 200 day simple moving average of $983.91.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Wednesday, February 4th. The company reported $7.54 EPS for the quarter, beating analysts’ consensus estimates of $7.48 by $0.06. Eli Lilly and Company had a net margin of 31.66% and a return on equity of 102.94%. The firm had revenue of $19.29 billion during the quarter, compared to analyst estimates of $17.85 billion. During the same period in the previous year, the business earned $5.32 EPS. The business’s revenue for the quarter was up 42.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. On average, analysts predict that Eli Lilly and Company will post 33.9 earnings per share for the current year.

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.